08/06/2026
TAMP spent Five days at JSM 2026 in Boston with our partners at Hill Research AI, and I am still working through the conversations.
We came to booth 607 with a simple plan: put TriClick in front of the people who actually do this work. Biostatisticians. Statistical programmers. Clinical data managers. This is the crowd that will tell you inside of ninety seconds whether what you built is real or whether it is a slide deck.
They told us. Repeatedly. And then they asked for demos.
What I did not expect was the volume. We ran demos back to back, generating SDTM and ADaM specs in minutes and walking through TFL packages that used to take a team of nine six months to assemble. The most valuable moments were not the reactions to speed. They were the follow up questions from people who have spent twenty years in submission work and immediately started probing the edges: traceability, define.xml, audit trail, where the human review sits in the pipeline. That feedback is worth more to us than any pipeline number.
Senior leaders from several large pharma organizations stopped by and were direct about how this compares to what they have seen elsewhere. We also had good conversations with FDA attendees about how AI tooling in this space should align with the agency's guidance on AI in regulatory decision making.
To everyone who waited for a demo slot, sent a colleague over, or pushed back on something we showed you: thank you. The requests are in the queue and we are working through them this week.
Congratulations to the ASA on a strong meeting.
